AI-designed universal vaccine clears first human trial, targets future coronavirus threats with needle-free delivery
medicalxpress.com
The first human clinical trial of a universal Sarbeco coronavirus vaccine, developed by the University of Cambridge and spin-out DIOSynVax (DVX) Ltd, has shown that the vaccine is safe and has no significant side effects.